SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Jason O'Byrne, Executive Vice President and Chief Financial Officer, is stepping down effective August 3, 2026, to pursue another opportunity. While the filing also discloses the appointment of Brent Sabatini as interim principal financial officer, the principal disclosed action centers on the departure of the CFO, a named executive officer. The CFO departure is the material event driving the filing.
View raw filing on EDGAR →Steven M. Klein resigned from the FHLBNY's Board of Directors effective July 20, 2026, as a Member Director. Although the resignation was triggered by the merger of Northfield Bank (where he served as Chairman, President and CEO) into Columbia Bank, making him ineligible to serve under regulatory requirements, the core disclosed action is his departure from the board. This is a material governance event affecting the composition of the registrant's board of directors.
View raw filing on EDGAR →Syvia L. Magid resigned as a director of BayCom Corp and its subsidiary United Business Bank, effective July 22, 2026. The disclosure centers on a director's departure, not an appointment or compensation arrangement. Director departures are material to investors as they affect board composition and governance. The filing explicitly states the resignation was not due to disagreement, which is a standard disclosure but does not diminish the materiality of the departure itself.
View raw filing on EDGAR →Prof. Amnon Shashua, founder and CEO of Mobileye for 27 years, has informed the Board of his intention to step down as CEO upon appointment of a successor. The Board has offered him the role of Chairman. This represents a material leadership transition for the autonomous driving technology company.
View raw filing on EDGAR →Raymond T. White resigned as a board member of NN, Inc. effective immediately on July 20, 2026. The disclosure explicitly states the resignation was not due to disagreement, indicating a routine departure. Board departures are material events affecting the composition of the company's governance structure and would affect a reasonable investor's assessment of the registrant.
View raw filing on EDGAR →The 6-K discloses the resignation of two executives: Xiaojing Lu, a board member and committee participant, and Dan Qi, the Chief Risk Officer, both effective July 20, 2026. Both resignations are stated to be unrelated to disagreements with the Company. The principal disclosed action is the departure of these officers from their roles, which is the defining characteristic of exec_departure. The simultaneous departure of a director and a C-suite risk officer is material to investor assessment of governance and operational continuity.
View raw filing on EDGAR →Javier D. Ferrer announced his retirement as President and Chief Executive Officer effective August 31, 2026, after serving in that role since July 2025. The filing details his retirement benefits and consulting arrangement.
View raw filing on EDGAR →Benjamin Porter-Brown, Chief Medical Officer, transitioned from his full-time executive position to a consulting role effective July 24, 2026.
View raw filing on EDGAR →Benjamin Adams, Executive Vice President and Chief Legal Officer, notified the Company on July 20, 2026 of his intention to depart effective November 2, 2026, through participation in a Voluntary Retirement Program. While subsection (e) describes compensatory arrangements under the retirement program, the principal disclosed action is the departure of a named executive officer from a senior leadership position overseeing legal, privacy, public policy and enterprise risk functions.
View raw filing on EDGAR →Dr. Shantanu K. Gaur resigned as Chief Executive Officer and board member effective immediately on July 17, 2026. This is a departure of the company's principal executive officer, which is material to investors. While the filing notes the COO will oversee day-to-day operations, the central disclosed action is the CEO's resignation, not an appointment or compensation arrangement.
View raw filing on EDGAR →Mr. Stephen Ilott resigned from the Board of Directors effective July 19, 2026, due to personal reasons. As a board member and Audit Committee member, his departure is a material executive change that affects the composition of the company's governance structure and must be disclosed under Item 5.02.
View raw filing on EDGAR →The filing discloses that Mr. Nilay Patel, the Chief Legal Officer, will no longer serve as an officer of Cingulate Inc. effective August 3, 2026, due to the Board's decision to eliminate the Chief Legal Officer position. This is a departure of a named executive officer, treated as a termination without cause under his employment agreement. The elimination of a C-suite legal function is material to investors' assessment of the company's governance and operational structure.
View raw filing on EDGAR →Sharon McCollam, President and Chief Financial Officer, has announced her retirement later in 2026, with a transition period extending through February 27, 2027. This is a departure of a named executive officer from a senior C-suite position (CFO and President), which is material to investors assessing the company's leadership continuity and financial stewardship. The disclosure centers on the departure itself, not on compensation arrangements or the appointment of a successor.
View raw filing on EDGAR →Lawrence Brock's resignation as Chief People Officer, effective August 17, 2026, is the principal disclosed action. While the filing also mentions appointment of Dominique Baillet as his successor and severance/advisory arrangements, the core event is Brock's departure from his executive role. The departure of a C-suite officer (Chief People Officer) is material to investors assessing leadership stability and organizational continuity.
View raw filing on EDGAR →Andy Fox, Senior Vice President and Chief Credit Officer, separated from Meridian Corp on July 21, 2026 to pursue other opportunities. While the disclosure also mentions that Geoff Sheehan will assume the Chief Credit Officer role, the principal disclosed action is Fox's departure from a named executive officer position. The Chief Credit Officer is a material role at a financial institution (MRBK is a bank holding company), making this departure material to investors.
View raw filing on EDGAR →James K. Saccaro, Chief Financial Officer, resigned effective August 14, 2026, to pursue a role outside the medical technology industry. George Newcomb was appointed as interim CFO.
View raw filing on EDGAR →Anastasiia Reish resigned from all positions including President, Treasurer, Secretary, and Board membership on July 17, 2026.
View raw filing on EDGAR →Kenneth S. Booth resigned from the board of directors of Credit Acceptance Corporation on July 21, 2026. The filing explicitly states his departure and notes that the Board size was reduced from six to five directors in connection with his resignation. This is a clear director departure disclosure under Item 5.02, and board composition changes are material to investors assessing corporate governance.
View raw filing on EDGAR →Jonathan Robins, Chief Technology Officer, notified the Company on July 16, 2026 of his decision to separate from employment effective July 18, 2026, with final termination on October 16, 2026. While the MOU includes compensatory elements (continued healthcare benefits and COBRA coverage), the principal disclosed action is the departure of a named executive officer from a key technical leadership role. The separation agreement and release of claims are ancillary to the core event of his departure.
View raw filing on EDGAR →Ian T. Clark resigned from the Board of Directors of Corvus Pharmaceuticals, effective July 22, 2026, after over nine years of service. The disclosure centers on a director's departure, making this a clear exec_departure event. Board changes are material to investors assessing governance and leadership continuity.
View raw filing on EDGAR →All members of NSA's board of trustees and all officers ceased their positions effective at the merger closing. Named executive officers' employment was terminated without cause, triggering severance obligations under existing employment agreements.
View raw filing on EDGAR →R. Colby Slaughter, Senior Vice President, General Counsel and Corporate Secretary, notified the Company of his resignation effective August 7, 2026. The departure of a named executive officer holding senior legal and governance responsibilities is material to investors' assessment of the registrant's leadership and operational continuity.
View raw filing on EDGAR →Steven Ciardiello, Chief Accounting Officer, notified the Company on July 16, 2026 of his resignation effective August 28, 2026. The departure of a CAO is material to investors as it affects financial reporting oversight and internal controls, with the Company conducting a search for a successor.
View raw filing on EDGAR →Tracy Willis, Vice President and Chief Accounting Officer, notified the Company of her intention to resign effective August 6, 2026. While the filing also discloses that James Volk will assume her accounting responsibilities, the principal disclosed action is Willis's departure from an officer position. The departure of a Chief Accounting Officer is material to investors as it affects the registrant's financial reporting oversight and internal controls.
View raw filing on EDGAR →Douglas Kling, the Company's Chief Operating Officer, notified the company on July 16, 2026 of his resignation effective August 14, 2026 to join another biotech company as CEO. This is a clear executive departure of a named officer. While the filing mentions anticipated separation and advisor agreements, the principal disclosed action is Kling's departure from his COO role, making exec_departure the most salient classification.
View raw filing on EDGAR →Brandon Soto, Executive Vice President and Chief Financial Officer, is departing the Company effective August 15, 2026, to pursue a CEO position elsewhere. Joel Edwards has been appointed as Interim CFO to manage the transition.
View raw filing on EDGAR →The principal disclosed action is the termination of Geoffrey Hitchcock, Chief Revenue Officer, effective July 23, 2026, following a for-cause determination by the Board under his Employment Agreement. While the filing also discloses a subsequent civil complaint filed by Mr. Hitchcock (Item 8.01), the core Item 5.02 event is the executive departure itself. The for-cause termination and denial of severance benefits are material to investors assessing leadership stability and potential litigation risk.
View raw filing on EDGAR →J. Ted Nissen retired as Executive Vice President and Chief Banking Officer of the Company and President and CEO of the Bank, effective December 31, 2026, after 31 years with the organization. His departure triggers a leadership restructuring in which the CEO and President role will be split.
View raw filing on EDGAR →Casey Tansey, a Board member of 18+ years and early venture investor who led Inspire's Series A financing in 2007, notified the Company on July 16, 2026 of his decision to retire from the Board effective July 30, 2026. The Item 5.02 disclosure centers on his departure from the Board and decision not to stand for re-election, with no compensatory arrangements or new appointments disclosed. This is a material departure of a long-tenured director with significant historical influence on the company.
View raw filing on EDGAR →Michael D. Garrison, Executive Vice President and President of the Medical Essentials and BioPharma Systems segments, informed BD of his intention to retire effective October 2, 2026, after more than 20 years with the company. The filing also discloses an organizational restructuring whereby BioPharma Systems will report directly to the CEO following his departure.
View raw filing on EDGAR →Mingxiao (Gary) Guo, Senior Vice President and Chief Global Integrated Supply Chain Officer, is departing Trane Technologies effective August 1, 2026. The principal disclosed action is a named executive officer leaving the company. While the filing mentions a Separation Agreement and foregoing of clawback provisions, the core event is the departure itself, making exec_departure the most salient classification.
View raw filing on EDGAR →Matthew A. Hunton, Executive Vice President and President of Kemper Auto, is departing effective August 3, 2026, following a termination by the Company without cause. While severance benefits are mentioned, the principal disclosed action is the departure of a named executive officer from a significant operational role. This is material to investors as it affects leadership of a major business segment.
View raw filing on EDGAR →Curtis D. Hodgson, Executive Chairman and Board member of Legacy Housing Corporation, notified the Board on July 17, 2026 of his retirement effective July 21, 2026. The disclosure centers on his departure from executive and board positions, making this a clear executive departure event. The retirement of a company's Executive Chairman is material to investors as it represents a significant leadership change.
View raw filing on EDGAR →Kara Wilson, a director of Paychex, notified the Board on July 16, 2026 of her decision not to stand for re-election at the 2026 annual meeting, resulting in her departure from the Board. Although the departure is effective at the Annual Meeting (a future date), the principal disclosed action is a director's decision to leave office. The filing explicitly states the decision was not due to disagreement, and the Board's consequent reduction in size from 11 to 10 directors is a direct consequence of this departure.
View raw filing on EDGAR →Jack Mallers resigned as CEO and director effective July 20, 2026, with a separation agreement providing cash payments and vested equity. While the filing also discloses Raphael Zagury's appointment as CEO, the principal disclosed action centers on Mallers' departure—the triggering event that necessitated the leadership transition. The departure is material to a reasonable investor assessing the registrant's leadership continuity.
View raw filing on EDGAR →Mr. Niels Brix, an independent director since December 2021, resigned from the board and all committees effective immediately on July 7, 2026. The resignation was triggered by a lapse in the Company's directors and officers (D&O) insurance coverage, which the Company has since restored. This is a clear executive departure under Item 5.02, material because it involves loss of board representation and reflects a governance control failure (lapsed insurance).
View raw filing on EDGAR →All seven board members resigned effective upon Form 15 filing, and four key executives—CEO Stephen From, President Adam Sachs, CTO Sammy Khalifa, and Chief Medical Officer Dr. Barry Greene—were terminated effective July 21, 2026, in connection with the company's liquidation.
View raw filing on EDGAR →Lisa Bollinger, MD, Chief Medical Officer, resigned from her position effective immediately on July 19, 2026. The disclosure centers on the departure of a named executive officer from a key leadership role overseeing clinical and regulatory functions at a therapeutics company. While the company states it does not anticipate impact on clinical timelines, the departure of a CMO is material to investors assessing the company's development capabilities and execution risk.
View raw filing on EDGAR →Yakov Baranes, a board member of Charging Robotics Inc., tendered his resignation from the Board effective immediately on July 21, 2026. This is a clear departure of a director, which is material to investors as it affects board composition and governance. The disclosure explicitly states the resignation was for personal reasons and not due to disagreement, which is standard boilerplate but does not diminish the materiality of the board change itself.
View raw filing on EDGAR →Dr. Lynne Fahey McGrath, a director since the Company's June 2021 IPO, passed away on July 20, 2026. This constitutes a departure of a director from the Board due to death. The disclosure is material as it affects the composition of the Board and the loss of a long-serving director with significant biopharmaceutical expertise, which would affect a reasonable investor's assessment of the Company's governance and leadership.
View raw filing on EDGAR →Lynne M. Neel, Senior Executive Vice President overseeing critical functions (loan operations, deposit operations, electronic banking, and investor relations) at Embassy Bancorp, informed the company on July 16, 2026 of her intention to retire effective April 2, 2027. This is a departure of a named executive officer with significant operational responsibilities, disclosed under Item 5.02. The filing explicitly states her retirement is not due to disagreement, confirming it is a planned departure rather than a termination or dispute.
View raw filing on EDGAR →Dr. Gregory M. Sullivan, Chief Medical Officer, informed the Company on July 20, 2026 that he will retire from his role effective August 20, 2026. This is a clear executive departure disclosed under Item 5.02, representing the departure of a named officer from the Company.
View raw filing on EDGAR →Lori Gustafson, Executive Vice President and Chief Brand and Digital Officer, is separating from Marriott Vacations Worldwide effective July 31, 2026, due to elimination of her position in an internal reorganization. While the disclosure includes severance details ($1,425,000 plus potential performance payment), the principal disclosed action is her departure from the company. The event is material as it involves a named executive officer's separation and would affect investor assessment of leadership continuity.
View raw filing on EDGAR →Girish Venkatachaliah, Chief Technology Officer, is departing the Company effective August 1, 2026. While the disclosure also includes severance compensation details (cash severance of $766,063 and continued equity vesting through April 30, 2027), the principal disclosed action is the executive's departure. The severance and consulting arrangements are ancillary to the core event of the CTO leaving the organization.
View raw filing on EDGAR →William R. Nelson resigned from his position as President of the Republic Processing Group (RPG) effective August 28, 2026, to accept an executive opportunity elsewhere. While the filing also mentions Brent Shuman assuming the interim role, the principal disclosed action is Nelson's departure. The resignation of a division president is material to investors assessing management stability and operational continuity.
View raw filing on EDGAR →Adar Segal is stepping down from his position as Head of Automotive at Valens Semiconductor Ltd., with employment expected to terminate following a 180-day notice period. This is a clear executive departure disclosure. While the Head of Automotive may not be a named executive officer in the traditional sense, the formal announcement of a leadership departure in a 6-K filing indicates materiality to investors assessing the company's operational continuity and automotive segment leadership.
View raw filing on EDGAR →Jack Cho resigned from the Board on July 16, 2026, having served as chair of the Audit Committee and member of the Compensation Committee. While the filing also discloses appointments to fill the vacancies (Gonzalez, Gan, and Chu), the principal disclosed action centers on Cho's departure from the Board. The resignation is material as it affects board composition and audit committee leadership, though the non-disputed nature and immediate replacement mitigate some concern.
View raw filing on EDGAR →The filing discloses two executive departures: Richard Lowenthal's resignation from the Board of Directors effective immediately on July 15, 2026, and Sarina Tanimoto, M.D. (Chief Medical Officer), ceasing employment under a termination without cause on the same date. While severance and compensatory arrangements are mentioned, the principal disclosed action centers on these two individuals leaving their roles. The departure of a CMO is material to a pharmaceutical company's operations and investor assessment.
View raw filing on EDGAR →The filing discloses two significant executive departures: Ajay Kumar Dhadha resigned as Chairman and Director effective June 30, 2026, and Guy Ofir resigned as Chief Financial Officer, General Counsel, and Director effective July 16, 2026. While the section also mentions the appointment of Uri Tadelis as CFO, the principal disclosed actions center on the departures of two senior officers, including the CFO and Board Chairman. Both resignations are stated to be voluntary and without disagreement with the Company.
View raw filing on EDGAR →Nancy Lipson announced her resignation from the Board of Directors of Frontier Group Holdings, Inc., effective July 15, 2026, to pursue another business opportunity. This is a clear director departure disclosure under Item 5.02, with no indication of disagreement or controversy. Director changes are material to investors assessing governance and board composition.
View raw filing on EDGAR →